A detailed history of Condor Capital Management transactions in Incyte Corp stock. As of the latest transaction made, Condor Capital Management holds 22,365 shares of INCY stock, worth $1.54 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
22,365
Previous 22,527 0.72%
Holding current value
$1.54 Million
Previous $1.37 Million 8.28%
% of portfolio
0.14%
Previous 0.13%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$57.33 - $68.61 $9,287 - $11,114
-162 Reduced 0.72%
22,365 $1.48 Million
Q2 2024

Aug 08, 2024

SELL
$51.18 - $63.75 $20,472 - $25,500
-400 Reduced 1.74%
22,527 $1.37 Million
Q1 2024

May 09, 2024

BUY
$56.55 - $66.59 $648,063 - $763,121
11,460 Added 99.94%
22,927 $1.31 Million
Q4 2023

Feb 12, 2024

SELL
$52.16 - $64.19 $604,169 - $743,512
-11,583 Reduced 50.25%
11,467 $720,000
Q3 2023

Nov 09, 2023

BUY
$57.77 - $65.93 $39,168 - $44,700
678 Added 3.03%
23,050 $1.33 Million
Q2 2023

Aug 10, 2023

BUY
$60.95 - $75.51 $13,043 - $16,159
214 Added 0.97%
22,372 $1.39 Million
Q1 2023

May 10, 2023

SELL
$70.23 - $86.01 $18,962 - $23,222
-270 Reduced 1.2%
22,158 $1.6 Million
Q4 2022

Feb 07, 2023

SELL
$67.18 - $84.11 $39,300 - $49,204
-585 Reduced 2.54%
22,428 $1.8 Million
Q3 2022

Nov 10, 2022

BUY
$66.18 - $82.86 $59,495 - $74,491
899 Added 4.07%
23,013 $1.53 Million
Q2 2022

Aug 09, 2022

BUY
$66.18 - $83.18 $6,088 - $7,652
92 Added 0.42%
22,114 $1.68 Million
Q1 2022

May 10, 2022

BUY
$66.02 - $79.71 $1.45 Million - $1.76 Million
22,022 New
22,022 $1.75 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Condor Capital Management Portfolio

Follow Condor Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Condor Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Condor Capital Management with notifications on news.